What it is
PEG-MGF is a synthetic analogue of Mechano Growth Factor (MGF), the 24-amino-acid C-terminal E-domain peptide (sequence YQPPSTNKNTKSQRRKGSTFEEHK, peptide MW ≈ 2,948 Da) generated by alternative splicing of the IGF-1 gene. MGF corresponds to the IGF-1Ec isoform in humans (IGF-1Eb in rodents), produced via an exon 4 → exon 5 → exon 6 junction that introduces a 49 bp insert, causing a reading-frame shift and a completely different C-terminus compared to the systemic IGF-1Ea isoform. The E-domain peptide — which lacks the mature IGF-1 receptor-binding domain — is the biologically active fragment studied as exogenous MGF. PEGylation covalently attaches polyethylene glycol chains to the peptide, increasing hydrodynamic radius, total molecular weight (typically 4,000–6,000 Da depending on PEG chain length), and in-vivo stability. Unmodified MGF has a circulating half-life of roughly 5–7 minutes in rodent models; PEGylation is claimed to extend this to the 48–72 hour range by reducing glomerular filtration and shielding the peptide from peptidases — a claim grounded in the broader PEGylated-biologic literature rather than in a peer-reviewed PEG-MGF PK study. MGF is not FDA-approved in any form. PEG-MGF is sold as a research chemical.
In plain English
PEG-MGF is a lab-made copy of Mechano Growth Factor (MGF) — a short 24-amino-acid piece of an alternate version of the IGF-1 gene. When you damage a muscle, your body's IGF-1 gene gets spliced differently for a short time and makes this peptide instead of regular IGF-1. It acts as a local "start repairs" signal. Importantly, MGF is MISSING the part of IGF-1 that attaches to the normal IGF-1 receptor — so it works through some other, still-unidentified pathway. "PEG" stands for polyethylene glycol: chemists stick PEG chains onto the peptide to make it bigger and more stable, so it lasts longer in the body. In rats, natural MGF clears in 5–7 minutes. The PEG version is claimed to last 48–72 hours. That number comes from what PEG does for other drugs — not from any measurement of PEG-MGF in humans. No form of MGF is FDA-approved. PEG-MGF is sold only as a research chemical.
How it works
- 01
Alternative splicing of IGF-1 produces a mechanosensitive signal
Goldspink (2010, Endocrinology) reviewed the IGF-1 gene architecture showing that mechanical load and tissue damage shift splicing toward the IGF-1Ec (MGF) transcript. Hill & Goldspink (2003, J Physiol) demonstrated in rat muscle that MGF mRNA rises sharply in the first 24–48 hours after mechanical damage and then declines as systemic IGF-1Ea rises over 5–10 days, producing a temporally separated biphasic growth-factor response. This is the endogenous basis for positioning MGF as an early activation signal rather than a durable anabolic driver.
In plain English
Damaged muscle reads the IGF-1 gene a different way
Your body has one IGF-1 gene but reads it in different ways depending on what is happening. When a muscle gets damaged, the cell reads the gene to make MGF (the short, local "start repairs" signal) in the first 24–48 hours. Then, over the next 5–10 days, it switches to making regular IGF-1 (the systemic "build muscle" signal). So MGF is an early, short-term signal — not a long-term muscle-building driver.
- 02
Satellite cell activation and the myogenic program
Hill, Wernig & Goldspink (2003, J Anat) linked MGF expression to satellite-cell activation during local muscle injury and repair, coincident with upregulation of M-cadherin, Myf5, and MyoD. Dumont (2015, Semin Cell Dev Biol) placed MGF within the broader satellite-cell activation pathway that drives quiescent muscle stem cells into the cell cycle. The mechanistic point is that MGF is proposed to act on early-phase proliferation of satellite cells, whereas mature IGF-1Ea acts later to promote myoblast differentiation.
In plain English
It wakes up muscle stem cells so they can divide and repair
Muscles keep a pool of sleeping stem cells (called satellite cells) for repairs. When muscle is damaged, MGF appears to be one of the signals that wakes those stem cells up and tells them to divide. Regular IGF-1 comes later to help them mature into new muscle fibers. Simplified: MGF handles the early "wake up and multiply" step; IGF-1 handles the later "grow up and become muscle" step.
- 03
Partial IGF-1R interaction and downstream PI3K/Akt–mTOR signaling
Tonkin (2012, Front Endocrinol) critically reviewed the mechanism and concluded that the MGF E-peptide does not engage the mature IGF-1 receptor in the canonical way (the IGF-1R binding domain is absent from the E-peptide). It is proposed to act through a distinct, still poorly defined tissue-local receptor or accessory mechanism that converges on PI3K/Akt and mTOR to drive protein synthesis and cell survival. The specific receptor identity remains unresolved in 2026 — this is the central unanswered mechanistic question.
In plain English
It does NOT hit the normal IGF-1 receptor — and no one has found what it does hit
This is a big deal: the piece of IGF-1 that attaches to the IGF-1 receptor is MISSING from MGF. So MGF cannot work through the normal IGF-1 pathway. It clearly does something — it drives known cell-survival signals (PI3K/Akt/mTOR) — but no one has identified the specific spot on a cell that MGF attaches to. As of 2026, this is the biggest unanswered question in MGF biology.
- 04
Neurogenesis in the aging brain
Kandalla (2017, Mol Brain) showed that intracerebroventricular delivery of MGF in aged mice increased the number of proliferating neural progenitor cells in the dentate gyrus, rescued age-related decline in adult hippocampal neurogenesis, and improved performance on hippocampus-dependent learning tasks. This is single-lab rodent evidence; no analogous human study exists.
In plain English
In aging mice, it grew new brain cells — but only in one study
In a single 2017 study, MGF was pumped directly into the brains of old mice. Brain stem cells in the memory region multiplied, and the mice did better on memory tasks. One lab. Mice only. Not reproduced. No human study exists.
- 05
Cardiac protection after infarction
In a sheep model of myocardial infarction, intracoronary MGF-24aa-E peptide delivery improved post-MI hemodynamic recovery versus mature IGF-1, consistent with PI3K/Akt-mediated cardiomyocyte survival. This is the only published large-animal cardiac data and has not been independently replicated; there is no human cardiac MGF trial.
In plain English
In sheep, it helped the heart recover after a heart attack — one study
In sheep given heart attacks, infusing MGF directly into the heart's arteries worked better than regular IGF-1 for recovery. Consistent with its known cell-survival signals. But this is the ONLY big-animal heart study, it was done by one lab, and no one has reproduced it. No human heart trial exists.
- 06
The PEGylation half-life claim
The 48–72 hour half-life extension claim is extrapolated from the general PEGylation platform literature (Turecek 2016, Expert Opin Emerg Drugs; Huckaby & Lai 2018; Wang 2024, Front Pharmacol) and the >30 FDA-approved PEGylated biologics (pegfilgrastim, pegaspargase, peginterferon, etc.) that show increased molecular size reduces renal clearance and shields peptides from proteolysis. No peer-reviewed PK study of PEG-MGF specifically in humans or in large animals has been published. The PK extension should be read as a platform-level inference, not a measured parameter for this molecule.
In plain English
The "longer half-life" claim is borrowed from other PEG drugs
PEG is a common trick for making drugs last longer — it makes the molecule bigger so the kidneys can't filter it out, and it shields the peptide from breakdown enzymes. More than 30 FDA-approved drugs use it (like pegfilgrastim for low white blood cell counts). The common claim of a 48–72 hour half-life for PEG-MGF is based on what PEG does for THOSE drugs. No one has actually measured PEG-MGF half-life in a human or large animal. Treat the claim as an educated guess, not a fact.
- 07
What is NOT known about the mechanism
The specific MGF receptor has not been identified. Whether PEG-MGF reaches skeletal muscle satellite cells after subcutaneous injection at physiologically relevant concentrations has not been demonstrated in humans. Repeated-dose immunogenicity of the PEG-peptide conjugate — a known concern for PEGylated biologics, where anti-PEG antibodies can accelerate clearance — has not been characterized for this molecule. Dose–response in humans is entirely unstudied.
In plain English
What we still don't know
The specific cell receptor MGF attaches to has never been found. No one has shown that PEG-MGF injected under the skin actually reaches muscle stem cells in humans at useful concentrations. PEG-wrapped drugs can trigger antibodies against the PEG itself after repeated doses — that has not been studied for PEG-MGF. The right human dose, how often to give it, and how to give it are all unstudied.